Academic Journal
Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis.
| العنوان: | Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis. |
|---|---|
| المؤلفون: | Pedrani, M., Salfi, G., Merler, S., Testi, I., Cani, M., Turco, F., Trevisi, E., Tortola, L., Treglia, G., Di Tanna, G.L., Vogl, U., Gillessen, S., Theurillat, J.P., Pereira Mestre, R. |
| المصدر: | European urology oncology, vol. 7, no. 6, pp. 1199-1215 |
| سنة النشر: | 2024 |
| المجموعة: | Université de Lausanne (UNIL): Serval - Serveur académique lausannois |
| مصطلحات موضوعية: | Humans, Male, Prostatic Neoplasms/genetics, Prostatic Neoplasms/pathology, Prostatic Neoplasms/therapy, Prostatic Neoplasms/mortality, Prostatic Neoplasms/drug therapy, Repressor Proteins/genetics, Nuclear Proteins/genetics, Mutation, Prognosis, Abiraterone, Androgen deprivation treatment, Docetaxel, Meta-analysis, Predictive, Prostate cancer, Speckle-type POZ, Survival, Systematic review |
| الوصف: | Mutations in the speckle-type POZ (SPOP) gene are frequently identified in prostate cancer (PC); yet, prognostic implications for affected patients remain unclear. Limited consensus exists regarding tailored treatments for SPOP-mutant (SPOPmut) PC. To elucidate the prognostic and predictive significance of SPOP mutations across distinct PC stages and treatments. A systematic literature search of PubMed, Embase, and Scopus was conducted up to January 29, 2024. The meta-analysis included studies comparing survival outcomes between SPOPmut and SPOP wild-type (SPOPwt) PC. From 669 records, 26 studies (including five abstracts) were analyzed. A meta-analysis of metastasis-free survival in localized (hazard ratio [HR]: 0.72, 95% confidence interval [CI]: 0.59-0.88; p < 0.01) and overall survival (OS) in metastatic PC (HR: 0.64, 95% CI: 0.53-0.76; p < 0.01) showed a favorable prognosis for patients with SPOPmut PC. In metastatic settings, SPOP mutations correlated with improved progression-free survival (PFS) and OS in patients undergoing androgen deprivation therapy ± androgen receptor signaling inhibitor (HR: 0.51, 95% CI: 0.35-0.76, p < 0.01, and HR: 0.60, 95% CI:0.46-0.79, p < 0.01, respectively). In metastatic castration-resistant PC, only abiraterone provided improved PFS and OS to patients with SPOP mutations compared with patients with SPOPwt, but data were limited. SPOP mutations did not correlate with improved PFS (p = 0.80) or OS (p = 0.27) for docetaxel. Patients with SPOPmut PC seem to exhibit superior oncological outcomes compared with patients with SPOPwt. Tailored risk stratification and treatment approaches should be explored in such patients. Speckle-type POZ (SPOP) mutations could be a favorable prognostic factor in patients with prostate cancer (PC) and may also predict better progression-free and overall survival than treatment with hormonal agents. Therefore, less intensified treatments omitting chemotherapy for patients with SPOP-mutant PC should be explored in ... |
| نوع الوثيقة: | article in journal/newspaper review |
| وصف الملف: | application/pdf |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/38704358; info:eu-repo/semantics/altIdentifier/eissn/2588-9311; info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_18369D0EF1D25; https://serval.unil.ch/notice/serval:BIB_18369D0EF1D2; https://serval.unil.ch/resource/serval:BIB_18369D0EF1D2.P001/REF.pdf |
| DOI: | 10.1016/j.euo.2024.04.011 |
| الاتاحة: | https://serval.unil.ch/notice/serval:BIB_18369D0EF1D2 https://doi.org/10.1016/j.euo.2024.04.011 https://serval.unil.ch/resource/serval:BIB_18369D0EF1D2.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_18369D0EF1D25 |
| Rights: | info:eu-repo/semantics/openAccess ; CC BY-NC-ND 4.0 ; https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| رقم الانضمام: | edsbas.3BF01A0C |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.euo.2024.04.011 |
|---|